Recursion Announces Completion of NVIDIA-Powered BioHive-2 AI Pharma Supercomputer
Portfolio Pulse from Benzinga Newsdesk
Recursion (NASDAQ:RXRX) has completed its NVIDIA-powered AI supercomputer, BioHive-2, featuring 63 DGX H100 systems and 504 NVIDIA H100 Tensor Core GPUs. This supercomputer is four times faster than its predecessor, BioHive-1, making it the fastest supercomputer owned by a pharmaceutical company globally.
May 13, 2024 | 9:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NVIDIA's involvement in powering Recursion's BioHive-2 supercomputer with its DGX H100 systems and H100 Tensor Core GPUs underscores its leading position in AI and computing technologies, potentially boosting investor confidence.
NVIDIA's technology being at the core of the world's fastest pharmaceutical supercomputer not only showcases its advanced AI capabilities but also strengthens its position in the tech market. This could lead to increased investor confidence and a positive impact on NVDA's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Recursion's completion of the BioHive-2 supercomputer, significantly enhancing its drug discovery capabilities, positions the company at the forefront of pharmaceutical innovation.
The completion of BioHive-2 significantly enhances Recursion's drug discovery capabilities, potentially leading to faster and more efficient development of new drugs. This technological advancement could attract investor interest, driving up RXRX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100